Vaccine for mycoplasma infection
Inventors
Matsuda, Kazuhiro • Ichiyama, Koji • Matsuda, Sachie • Sasaki, Yuko • Arakawa, Yoshichika • Harasawa, Ryo • Nishida, Yoshihiro • Katayama, Norio • Endo, Yasuo • Nomura, Nobuo
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10232026-B2
Publication Date
2019-03-19
Expiration Date
Abstract
Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
Core Innovation
The invention relates to pathogenic bacterium-mimic particles that include liposome particles having at least one purified lipid antigen specific to a pathogenic bacterium as a liposome-constituting lipid component. The lipid component consists of the purified lipid antigen alone or a mixture of the purified lipid antigen, phospholipid, and cholesterol. The bacterium-mimic particles are configured to cause an immune response in an organism susceptible to being infected with the pathogenic bacterium.
A specific embodiment provides mycoplasma-mimic particles composed of liposome particles including at least one purified mycoplasma-specific glycolipid antigen as a liposome-constituting lipid component. The purified mycoplasma-specific glycolipid antigen is chemically or enzymatically synthesized, then separated and purified, and is used as an antigen to form the liposome particles.
In representative embodiments, the antigen-containing liposome component is combined with phospholipid and cholesterol, including phosphatidyl choline, phosphoglycerol, and/or cholesterol, to form stabilized, uniform liposome particles that mimic pathogenic bacteria. The disclosed evaluation and outcomes include immune responses, including humoral (IgG and IgM), mucosal (IgA), and cellular responses (IFN-b3), and the particles are disclosed for preventing and/or treating disease caused by Mycoplasma infection.
Claims Coverage
The independent claims provide coverage for two related particle concepts: (i) general pathogenic bacterium-mimic particles and (ii) Mycoplasma-mimic particles. Across the families supported by the partial content, the inventive focus comprises 3 principal categories of inventive features.
Purified lipid antigen as a liposome-constituting lipid component for bacterium mimic particles
Pathogenic bacterium-mimic particles comprising liposome particles including at least one purified lipid antigen specific to a pathogenic bacterium as a liposome-constituting lipid component, where the lipid component consists of the purified lipid antigen alone or a mixture of the purified lipid antigen, phospholipid and cholesterol.
Immune-response-capable particles for organisms susceptible to pathogenic bacterium infection
Pathogenic bacterium-mimic particles that can cause immune response in the immune system in an organism which is susceptible of being infected with the pathogenic bacterium.
Purified Mycoplasma-specific glycolipid antigen synthesized and purified for liposome constituting component
Mycoplasma-mimic particles comprising liposome particles including at least one purified mycoplasma-specific glycolipid antigen as a liposome-constituting lipid component, wherein the at least one purified mycoplasma-specific glycolipid antigen is chemically or enzymatically synthesized, and then separated and purified.
The claim coverage centers on liposome particles acting as bacterium-mimic immune stimulants by incorporating purified, species-specific lipid antigens as liposome-constituting components, with a specific Mycoplasma embodiment requiring chemically or enzymatically synthesized and separated/purified mycoplasma-specific glycolipid antigen for use in Mycoplasma-mimic liposome particles.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?